Cold chain under extreme constraints: lessons from ATMPs 

Cold chain failures are typically understood as temperature problems. In reality, they are often model failures.

Products are rarely lost due to lack of temperature control. Losses occur because supply chains are built on common beliefs that silently break under the stress of cold chain requirements.

Advanced therapy medicinal products (ATMPs) expose these weaknesses with unusual clarity. They do not introduce entirely new challenges, but they remove the buffers that hide structural fragility in standard pharma supply chains.

ATMPs as a supply chain stress test

ATMP supply chains operate under conditions that push logistics systems to their limits:

• Shelf life measured in hours or days after manufacturing

• Patient-specific manufacturing and a strict chain of identity ensuring patient–product traceability at every step

• Near-zero inventory buffers

• Ultra-cold or cryogenic storage requirements

• Administration within precise time windows

Under these constraints, conventional supply chain strategies often fail, and even minor disruptions can quickly cascade into product loss or missed treatment windows.

Traditional exception management – reacting after an alert occurs – is too slow. Effective ATMP supply chains must be proactive in responding to disruptions. They need predictive controls and orchestrated responses that surface risk early enough to adjust, not just to document a failed shipment.

The stakes are too high to accept these cold chain risks

Because ATMPs are often manufactured for a single, named patient, losing the chain of identity or delaying delivery is functionally equivalent to losing the product itself: it is not possible to re-allocate a dose to another patient, and there is no way to replace the lost treatment with existing inventory.

These risks are not hypothetical. One in five temperature-sensitive shipments is impacted by product damage and recalls. Experts estimate that such cold chain failures cost pharma companies $35 billion per year.  

Successful ATMP supply chains treat time, temperature and chain of identity as a single, combined viability constraint. By coordinating manufacturing, logistics and clinical administration, pharma organizations can safeguard their products even when individual steps encounter challenges.

Beyond ATMPs: implications for the broader life science supply chain

ATMPs demonstrate that reliability is an architectural requirement as well as an operational one. Similar dynamics are spreading across life sciences:

• Increasing personalization and smaller batch sizes

• More complex global manufacturing networks

• Greater time sensitivity in clinical and commercial flows

• Heightened regulatory and financial exposure 

As buffers shrink and interdependencies tighten, conventional cold chains begin to display behaviors once associated primarily with advanced therapies.

To manage these heightened constraints in pharma supply chains, organizations need to move beyond component optimization toward system-level design, simulation and orchestration. By adopting this level of control, they can proactively navigate disruptions, maintain compliance and reliably deliver therapies to patients around the world.